# Blood Group Typing Market

> Blood Group Typing Market Research Report By Technology (Serological Testing, Molecular Testing, Microarray Technology, Next Generation Sequencing), By Product Type (Reagents, Instruments, Software, Consumables), By Application (Blood Donation, Transfusion, Organ Transplantation, Disease Diagnosis), By End User (Hospitals, Blood Banks, Diagnostic Laboratories, Research Institutions) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Industry Forecast to 2035.

- **Forecast Period:** 2026-2035
- **CAGR:** 8.2%
- **2025:** USD 2.41 Billion
- **2035:** USD 5.31 Billion
- **Key Players:** Bio-Rad Laboratories, Grifols S.A., QuidelOrtho, Immucor (Werfen), Quotient Limited, BAG Healthcare GmbH, Beckman Coulter (Danaher), Agena Bioscience

**Report ID:** MRFR/MED/4949-HCR · **Pages:** 90 · **Author:** Rahul Gotadki & Kinjoll Dey · **Last Updated:** July 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/blood-group-typing-market-6410

---

## Market Summary

According to Market Research Future analysis, the Blood Group Typing Market Size was valued at USD 2,493.86 Million in 2024. The market is projected to grow from USD 2,715.86 Million in 2025 to USD 6,371.87 Million by 2035, registering a CAGR of 8.9% during the forecast 2025–2035. North America led the market with over 50.10% share, generating around USD 1249.4 million in revenue.
 
Rising demand for safe blood transfusions, growing number of blood donation drives, and adoption of advanced diagnostic technologies are driving the Blood Group Typing Market, enabling faster, accurate typing and improved patient care globally.
 
According to WHO, over 112.5 million blood donations are collected worldwide annually, with compatibility testing crucial for safety. CDC reports that precise blood typing prevents thousands of adverse transfusion reactions each year in the U.S., emphasizing growing market need.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Rising global surgical volumes | ~20% | Global | Long-term (≥4 yr) | [5] |
| Government blood-safety mandates | ~18% | Asia-Pacific, Africa | Medium-term (2–4 yr) | [1] |
| Automation of blood-bank workflows | ~17% | North America, Europe | Short-term (≤2 yr) | [3] |
| Molecular genotyping adoption | ~15% | North America, Europe | Medium-term (2–4 yr) | [7] |
| An aging population and chronic disease burden | ~13% | Europe, Japan | Long-term (≥4 yr) | [8] |
| Hospital system consolidation and bundled procurement | ~10% | North America | Medium-term (2–4 yr) | [9] |
| Expanding voluntary blood-donation campaigns | ~7% | Asia-Pacific, South America | Short-term (≤2 yr) | [6] |

### Rising Global Surgical Volumes

Global surgical demand continues to escalate, driven by aging populations and an increasing prevalence of chronic conditions. According to industry analysis, the surgical procedures market is experiencing sustained growth as elderly demographics—a group with higher clinical requirements—expand globally. This upward trajectory in procedures directly increases the necessity for robust blood transfusion support and associated diagnostic testing.

### Government Blood-Safety Mandates

National health authorities are actively strengthening transfusion safety through increased regulatory oversight and infrastructure investment. In India, annual blood collections grew to 14.6 million units by 2024, reflecting systemic efforts to improve service delivery and quality assurance. Similarly, China recorded 15.11 million voluntary blood donations in 2025, with national health policies emphasizing enhanced safety protocols and testing capabilities.

### Automation of Blood-Bank Workflows

Laboratories are increasingly adopting automation to mitigate ongoing personnel shortages and operational pressures. While staffing conditions in U.S. medical laboratories have improved from pandemic-era extremes, vacancy rates remain well above pre-pandemic norms. To address these persistent recruitment and retention challenges, facilities are investing in walk-away automated platforms that streamline complex workflows and maintain consistent diagnostic service levels

### Molecular Genotyping Adoption

Clinical management protocols for conditions like sickle-cell disease are evolving to prioritize precision medicine, specifically through improved transfusion support guidelines. There is a growing clinical emphasis on advanced diagnostic methods, including molecular genotyping, better to resolve complex antigen profiles in chronically transfused patients. This shift toward high-resolution testing is essential for ensuring long-term patient safety and efficacy.

## Restraints

## Restraints Impact Analysis

The restraint impacts below are directional estimates reflecting each factor's drag on overall growth. They are not directly subtracted from the CAGR.

| Restraint | ~% Negative Impact | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| High capital cost of automated platforms | ~–25% | Emerging markets | Short-term (≤2 yr) | [11] |
| Reagent cold-chain and shelf-life limitations | ~–20% | Africa, South Asia | Long-term (≥4 yr) | [12] |
| Regulatory fragmentation across jurisdictions | ~–20% | Global | Medium-term (2–4 yr) | [13] |
| Reimbursement compression in mature markets | ~–18% | North America, Europe | Medium-term (2–4 yr) | [14] |
| Data interoperability and LIS integration gaps | ~–17% | Global | Short-term (≤2 yr) | [15] |

### High Capital Cost of Automated Platforms

Automated blood-typing analyzers often require significant upfront capital expenditure, with advanced systems frequently exceeding USD 150,000. For small or resource-constrained facilities, these costs remain prohibitive, particularly when vendor-mandated minimum test volumes for reagent-rental agreements cannot be met. This economic barrier limits the widespread adoption of high-throughput automation in regions where improving diagnostic infrastructure is most critical for patient safety.

### Reagent Cold-Chain and Shelf-Life Limitations

Blood-banking reagents, such as monoclonal antisera, require strict 2–8°C storage to ensure diagnostic integrity, with typical shelf lives limited to 12–18 months. In tropical environments, power instability frequently disrupts cold-chain logistics, leading to wastage rates that can exceed 15%. Such inefficiencies inflate per-test operational costs and often force facilities to restrict their antigen testing panels significantly.

### Regulatory Fragmentation

In-vitro diagnostic (IVD) manufacturers face high cost and time burdens due to divergent global regulatory pathways, such as the EU’s IVDR and individual national frameworks. Compliance and conformity assessments for complex devices can require investments exceeding USD 100,000 for technical documentation and quality system audits. These regulatory complexities can extend product launch timelines by 12–18 months, constraining competition.

## Opportunities

## Blood Group Typing Market Opportunities

### Point-of-Care Blood Typing in Emergency and Military Settings

Rapid, bedside blood-typing devices that deliver ABO/Rh results within minutes are increasingly prioritized by military health systems and emergency departments. These field-deployable kits allow for immediate transfusion decisions, which are critical in trauma scenarios. As global surgical procedures exceed 360 million annually, integrating portable diagnostics into forward surgical teams and emergency units enhances operational readiness and life-saving transfusion capabilities worldwide.

### AI-Integrated Image Interpretation

Computer-vision algorithms, when applied to gel-card reaction images, are achieving high concordance rates with expert manual interpretations. By embedding these specialized software models into existing laboratory analyzers, vendors can improve diagnostic accuracy and boost productivity without requiring full hardware replacements. This digital integration facilitates real-time data analysis, reducing manual touchpoints and streamlining complex blood-banking workflows for modern clinical environments.

### Emerging-Market Infrastructure Buildout

Access to safe blood remains a challenge in sub-Saharan Africa, where donation rates often fall below the World Health Organization’s recommended threshold of 10 units per 1,000 population. As initiatives under the African Union’s Agenda 2063 prioritize health infrastructure modernization, significant opportunities emerge for vendors providing affordable, robust instrument portfolios to help bridge the critical gap in transfusion services.

### Data Monetization Through Digital Donor Registries

National blood services are increasingly digitizing donor phenotype databases to enhance inventory management and rare-donor recruitment. This systematic transition enables the generation of comprehensive, anonymized datasets. Licensing such aggregate analytics to pharmaceutical companies for epidemiological research and clinical studies—including investigations into hemolytic diseases—represents a growing, data-driven business model that adds long-term value to national transfusion health systems.

## Future Outlook

## Blood Group Typing Market Future Outlook

### AI-Driven Antibody Identification

Machine-learning algorithms are set to streamline complex antibody identification, which currently requires significant manual expertise. By 2030, advanced predictive models trained on extensive reaction data are expected to reduce turnaround times for antibody characterization significantly. This technological evolution will support laboratory staff in managing increased workloads, enhancing matching accuracy for multiply-transfused patients, and improving overall transfusion safety and operational efficiency globally.

### Platform Consolidation and Bundled Economics

Health systems are increasingly seeking integrated procurement strategies that bundle analytical platforms, reagents, and technical support under unified, long-term agreements. This consolidation trend toward maximizing operational efficiency and reducing costs per test within established health frameworks. By 2030, these comprehensive procurement models are projected to become the standard for modernizing blood transfusion infrastructure across diverse clinical settings in many nations.

### Precision Transfusion and Extended Genotyping

Clinical transfusion guidelines are evolving to prioritize precision, necessitating extended antigen matching beyond ABO/Rh systems for patients with conditions like sickle-cell disease. This shift requires the integration of molecular genotyping technologies into routine laboratory workflows to resolve complex antigen profiles. Such advancements are critical for minimizing alloimmunization risks and ensuring optimal, individualized treatment outcomes for patients requiring frequent, long-term transfusion support.

### Sustainability and Reagent Innovation

The global diagnostics sector is under increasing pressure to enhance sustainability by reducing cold-chain dependence and minimizing plastic waste. Developments in lyophilized reagents and room-temperature-stable technologies are critical for improving diagnostic accessibility in resource-limited settings. Vendors focusing on shelf-stable, environmentally sustainable solutions will be better positioned to support national blood systems, ensuring reliable diagnostic capabilities regardless of regional infrastructural constraints.

## Segment Insights

## Blood Group Typing Market Segmentation

### By Product

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Consumables | 44.3% share (2025) | Recurring reagent and test-card purchases |
| Instruments | USD 0.84 Billion (2025) | Automation replacement cycles |
| Services | 11.1% CAGR (2026–2035) | Reference-lab outsourcing and managed services |

Consumables dominate the Blood Group Typing Market by product because every test requires disposable reagents, gel cards, or microplate kits, regardless of the instrument platform. Vendors strategically price instruments at or near cost to lock in multi-year consumable supply agreements—a razor-and-blade model that generates predictable recurring revenue.

Services represent the fastest-growing product category as hospital groups outsource complex reference testing—rare antigen identification, crossmatch resolution, and neonatal workups—to specialized laboratories that maintain broader antisera inventories and deeper expertise.

### By Technique

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Serology Assay-Based | 53.2% share (2025) | Routine ABO/Rh and antibody screening |
| PCR-Based & Microarray | USD 0.81 Billion (2025) | Extended genotyping for transfusion-dependent patients |
| Others (incl. NGS) | 13.2% CAGR (2026–2035) | Complex variant resolution and research applications |

Serology remains the backbone of everyday blood typing—fast, inexpensive, and universally standardized. Gel-card column agglutination has largely replaced tube testing in developed markets, offering superior reproducibility and digital-image traceability.

Molecular methods are gaining share as clinical protocols expand the required antigen-matching panel. PCR-based platforms can genotype dozens of blood-group antigens from a single DNA extraction, making them indispensable for patients receiving chronic transfusion support.

### By Test Type

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| ABO Blood Tests | 37.8% share (2025) | Universal pre-transfusion requirement |
| Antibody Screening | USD 0.77 Billion (2025) | Regulatory mandate for all transfusion recipients |
| Antigen Typing & Others | 12.3% CAGR (2026–2035) | Expanded matching for complex clinical cases |

ABO classification is the single most performed blood-typing test globally, required before every transfusion, organ transplant, and many surgical procedures. Its dominance in the Blood Group Typing Market is structural—no clinical scenario bypasses this step.

Antigen typing beyond ABO/Rh is the fastest-expanding test category as clinical evidence mounts that extended matching reduces alloimmunization rates, particularly in sickle-cell and thalassemia populations where patients receive transfusions for decades.

### By End User

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Hospitals | 48.2% share (2025) | Bedside and blood-bank laboratory testing |
| Diagnostic Laboratories & Others | 14.3% CAGR (2026–2035) | Reference testing and centralized screening |

Hospitals account for the largest end-user share of the Blood Group Typing Market because transfusion decisions are made at the point of care, and regulatory frameworks require on-site blood-bank laboratories in facilities performing surgery. Stand-alone diagnostic laboratories are growing faster as regional health systems centralize testing to achieve economies of scale.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Key Metric | Primary Investment Themes |
| --- | --- | --- |
| North America | 35.5% share (2025) | Regulatory compliance, automation, bundled procurement |
| Europe | 28.0% share (2025) | EU IVDR transition, centralized blood services |
| Asia-Pacific | 9.4% CAGR (2026–2035) | Government blood-safety programs, hospital expansion |
| South America | USD 0.18 Billion (2025) | Public blood-bank modernization |
| Middle East & Africa | USD 0.17 Billion (2025) | Multilaterally funded infrastructure projects |
| Total | USD 2.41 Billion (2025) | — |

The Blood Group Typing Market exhibits a clear two-tier geographic structure: mature, compliance-driven markets in North America and Europe that emphasize platform standardization, and high-growth markets in Asia-Pacific and South America where infrastructure investment is the primary catalyst.

### North America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| United States | 78% of regional share | AABB standards and CMS reimbursement |
| Canada | 14% of regional share | Canadian Blood Services centralized purchasing |
| Mexico | 8.6% CAGR | COFEPRIS regulatory modernization |

The United States remains the single largest national market for blood typing, underpinned by approximately 13.6 million red-cell units transfused annually and a regulatory environment that mandates dual-verification testing [[9]](https://aabb.org). Canada's consolidated blood-service model (Canadian Blood Services and Héma-Québec) favors large platform tenders that create winner-take-all dynamics for instrument vendors.

### Europe

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Germany | 24% of regional share | DRK blood service network |
| United Kingdom | CAGR 7.8% | NHS Blood and Transplant digital overhaul |
| France | 19% of regional share | EFS centralized testing |
| Italy | USD 0.09 Billion | Regional transfusion-center upgrades |
| Spain | CAGR 7.5% | Autonomous-community procurement reforms |
| Nordic Countries | 9% of regional share | Shared Scandinavian reference-lab model |
| Russia | CAGR 8.4% | Federal blood-service modernization decree |
| Rest of Europe | USD 0.07 Billion | EU cohesion fund health grants |

The EU shapes Europe's Blood Group Typing Market In Vitro Diagnostic Regulation (IVDR), which took full effect in May 2024 and reclassified blood-grouping reagents as high-risk Class D devices [[13]](https://ec.europa.eu). This regulatory upgrade is forcing smaller reagent manufacturers to either invest heavily in conformity assessment or exit the market, concentrating supply among global players.

### Asia-Pacific

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| China | 31% of regional share | NHSA universal testing mandates |
| India | CAGR 10.8% | NBTC blood-bank expansion |
| Japan | 22% of regional share | Aging population, JRC procurement |
| South Korea | CAGR 9.1% | Korean Red Cross automation program |
| ASEAN | USD 0.05 Billion | WHO-supported capacity building |
| Rest of Asia-Pacific | CAGR 8.9% | Hospital construction pipelines |

Asia-Pacific's growth in the Blood Group Typing Market is concentrated in two powerhouses: China, where the National Healthcare Security Administration has mandated molecular screening for all donated blood by 2026, and India, where the NBTC's phased modernization plan targets 4,500 upgraded blood banks by 2028 [[6]](https://nbtc.naco.gov.in). Japan's market, while mature, benefits from one of the world's highest per-capita transfusion rates driven by its aging demographic.

### South America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Brazil | 58% of regional share | HEMOBRAS public procurement |
| Argentina | CAGR 8.1% | Provincial blood-center upgrades |
| Rest of South America | USD 0.04 Billion | PAHO technical assistance programs |

Brazil's HEMOBRAS agency centralizes blood-product procurement for the country's public health system (SUS), creating large-volume tenders that attract global vendors. The Blood Group Typing Market in South America overall is transitioning from manual tube methods to semi-automated gel-card platforms, a shift occurring roughly a decade behind North America.

### Middle East & Africa

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 29% of regional share | Vision 2030 healthcare investment |
| UAE | CAGR 8.7% | Dubai Health Authority lab centralization |
| South Africa | 24% of regional share | SANBS national testing network |
| Egypt | CAGR 9.3% | National Blood Transfusion Services reform |
| Rest of MEA | USD 0.04 Billion | African Union health-infrastructure targets |

The Middle East & Africa region presents a bifurcated picture: Gulf states are investing in state-of-the-art automated platforms comparable to European installations. At the same time, sub-Saharan Africa still relies heavily on manual methods. The South African National Blood Service (SANBS) operates one of the continent's most advanced testing networks, serving as a regional benchmark [[1]](https://who.int).

## Competitive Benchmarking

## Competitive Benchmarking

The Blood Group Typing Market is characterized by low concentration—the top five players collectively hold an estimated 45–52% revenue share, while dozens of regional reagent manufacturers serve local markets. The Herfindahl-Hirschman Index (HHI) sits below 1,000, confirming a fragmented competitive structure. Competition increasingly centers on integrated solutions rather than standalone instruments or reagents.

| Company | Est. Revenue Share Range | Key Offerings for the Blood Group Typing Market | Strategic Positioning |
| --- | --- | --- | --- |
| Bio-Rad Laboratories | ~10–14% | IH-500/IH-1000 gel-card analyzers, antisera and QC materials | Full-service automated platform leader |
| Grifols S.A. | ~9–13% | Erytra/Erytra Eflexis, DG Gel cards | European market penetration, reagent breadth |
| QuidelOrtho | ~8–12% | ORTHO VISION suite, BioVue cassettes | North American hospital stronghold |
| Immucor (Werfen) | ~7–11% | NEO Iris, Capture platforms, PreciseType HEA | Molecular and serologic dual portfolio |
| Quotient Limited | ~3–5% | MosaiQ microarray platform | Multiplexed next-gen testing technology |
| BAG Healthcare GmbH | ~3–5% | ID-gel cards, BAGene molecular kits | Mid-tier European and Asian presence |
| Beckman Coulter (Danaher) | ~2–4% | PK7400 automated system | Integration within the Danaher diagnostics ecosystem |
| Agena Bioscience | ~2–4% | MassARRAY genotyping platform | High-throughput molecular blood-group genotyping |
| Merck KGaA | ~1–3% | Millipore blood-banking reagents | Reagent supply-chain and OEM partnerships |
| Hemo bioscience | ~1–2% | ALBA and FIA typing systems | Emerging-market cost-competitive platforms |

## Recent News & Developments

## Recent News & Developments

- Grifols- (June, 2026)—Launched the Evanzys IH, a next-generation, modular, and fully automated system designed to enhance laboratory efficiency and flexibility in transfusion medicine.
- Devyser- (2026)—Launched its Genomic Blood Typing assay, a next-generation sequencing (NGS) solution that enables comprehensive genetic blood group and antigen analysis in one test.
- Haemonetics Corporation- (January 2025)—Agreed to sell its whole blood assets to GVS S.p.A for USD 67.1 million, aiming to streamline and sharpen its portfolio.

## Report Scope

## Blood Group Typing Market Report Scope

| Parameter | Detail |
| --- | --- |
| Market Scope | Global Blood Group Typing Market across products, techniques, test types, end users, and regions |
| Study Period | 2021–2035 |
| CAGR (Forecast Period) | 8.2% (2026–2035) |
| Market Size (2025) | USD 2.41 Billion |
| Market Size (2035) | USD 5.31 Billion |
| Fastest Growing Segments | Services (by product); NGS (by technique); Antigen typing (by test type); Asia-Pacific (by region) |
| Companies Profiled | 10 |
| Valuation Currency | USD Billion |

## Frequently Asked Questions

**Q: How do reagent-rental contracts affect laboratory purchasing decisions in the Blood Group Typing Market?**
A: Reagent-rental agreements eliminate upfront capital expenditure by placing instruments at no charge in exchange for committed consumable volumes. They lower entry barriers for smaller facilities but create long-term vendor lock-in that can limit technology flexibility [9].

**Q: What role does the EU IVDR reclassification play in reshaping competitive dynamics?**
A: Class D reclassification raises conformity-assessment costs to roughly USD 2–4 Million per product, forcing smaller manufacturers to consolidate or exit [13]. This accelerates market concentration toward global players with diversified regulatory portfolios.

**Q: How does extended antigen genotyping change per-patient testing economics?**
A: Molecular genotyping panels cost USD 50–120 per patient compared to USD 5–10 for basic serology, but reduce alloimmunization-related costs significantly [7]. The net clinical value proposition drives adoption in chronically transfused populations.

**Q: What infrastructure gaps limit the Blood Group Typing Market growth in sub-Saharan Africa?**
A: Unreliable cold chains, intermittent power supply, and a shortage of trained laboratory personnel constrain reagent utilization rates [1]. Tropicalized room-temperature platforms are needed to unlock this region's potential.

**Q: How are cybersecurity concerns affecting blood-bank information systems?**
A: Blood banks store sensitive donor health data subject to HIPAA and GDPR. Recent ransomware incidents targeting hospital networks have prompted investment in air-gapped LIS architectures and encrypted data transmission [15].

**Q: What distinguishes gel-card technology from solid-phase red-cell adherence methods?**
A: Gel-card systems use dextran-acrylamide columns to trap agglutinated cells, while solid-phase methods immobilize antigens on microplate wells [12]. Both offer superior standardization over tube testing, but gel cards dominate due to broader antigen menus.

**Q: How might liquid-biopsy platforms intersect with blood-typing workflows?**
A: Liquid-biopsy instruments already extract and analyze cell-free DNA, a capability adaptable to blood-group genotyping from plasma [18]. Convergence could enable combined oncology and immunohematology testing on shared platforms by 2030.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/blood-group-typing-market-6410*